GLP-1 agonists
DEGLP-1-Agonisten
GLP-1 receptor agonists (e.g. liraglutide, semaglutide, dulaglutide) mimic the incretin hormone glucagon-like peptide-1, stimulating glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite. Approved indications include type 2 diabetes and obesity; large trials demonstrate reduced cardiovascular events, now-approved kidney-disease risk reduction in type 2 diabetes with chronic kidney disease (semaglutide, FDA January 2025, FLOW trial), and investigational heart-failure symptom improvements in HFpEF. Longevity-relevant effects include weight loss, improved glycemia, and possible neuroinflammatory dampening. Off-label use purely for healthspan extension in metabolically healthy adults remains investigational. On 21 February 2025 the FDA declared the US semaglutide shortage resolved, ending the 503A/503B compounding window for semaglutide; tirzepatide compounding was similarly restricted after a 2024 preliminary-injunction denial, and the FDA proposed a permanent 503B bulks exclusion for semaglutide, tirzepatide, and liraglutide on 30 April 2026.